The observation that TRAIL may specifically kill cancer cells led to the development of TRAIL-receptor-based therapeutics which were intensively studied in pre-clinical as well as clinical trials for a variety of tumor entities (von Karstedt et al., 2017). The gene discussed is TNFSF10; the disease is neoplasm.